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Abstract 
CDRI 85/92 is an antiulcer pharmacophore and a proton pump inhibitor, which 
is in an advanced stage of preclinical trials. In view of its importance, 
pharmacokinetic and excretion were studied in Sprague Dawley  rats after 
administering 20 mg/kg oral and intravenous doses. The compound was 
detectable in the serum samples as early as 5 min post-oral administration. The 
compound was eliminated slowly from serum with an elimination half-life of 
2.1 h. Following the 20 mg/kg oral dose, maximum serum concentration (Cmax) 
was found to be 469.28 ± 45.52 ng/ml after 1.0 h. Based on AUC values, the 
absolute bioavailability of the CDRI 85/92 was 70.5% after oral administration. It 
was found to be excreted in urine (~15% of the dose) in intravenously treated 
(bile duct cannulated as well as noncannulated) rats, whereas bile and feces 
depicted insignificant levels of the compound. 
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Introduction 
Proton pumps (PPs), specific for H
+, K
+-ATPase, are responsible for the terminal step in 
the gastric acid secretion. Gastric acid secretion is significantly increased in multiple 
diseases and can lead to the formation of gastric ulcers [1]. Effective antiulcer 
pharmacophores and/or proton pump inhibitors are considered to be most promising in 
terms of providing acid suppression, pain relief and ulcer healing properties. At present, 
proton pump inhibitors (PPIs) remain the most effective available therapy. Compound 168  P. Srivastava:   
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CDRI-85/92, (5E)-2-oxo-5-(2-phenylethylidene)-1,3-oxazolidine-4-carboxylic acid (Fig. 1), 
developed by Central Drug Research Institute, in Lucknow, India, is an antiulcer 
pharmacophore. It possesses potent proton pump inhibition profile, providing a selective 
and competitive inhibition of the gastric proton pump and not inhibiting the proton pumps of 
the kidney and bone. Omeprazole (PPI), a drug of choice for treatment of antiulcer, is an 
irreversible proton pump inhibitor and decreases the inhibition % of the acidity by 
increasing the concentration of ATP [2]. The % inhibition in the free acidity of CDRI-85/92 
fairly compares with that of Omeprazole. Compound CDRI-85/92 has also shown good 
cytoprotective activity [3].  It possesses appreciable physicochemical properties {mol wt 
233; aqueous solubility >500µg/ml; log P 0.5; 2 pKa 3.65 and 11.98; Ka (absorption rate 
constant) 0.12 /h was alike at acidic and basic pHs, indicative of the presence of acidic 
and basic groups in the molecule; protein binding ~ 35%}. The compound is currently in an 
advanced stage of preclinical trials. However, no full insight of the pharmacokinetic and 
excretion data is available.  
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Fig. 1.  Chemical structure of CDRI-85/92 
To develop it as a candidate drug, the aim of this study was to determine the complete 
Pharmacokinetics and Excretion profile  of CDRI-85/92 in bile, feces and  urine,  after 
20 mg/kg oral and intravenous doses in male Sprague Dawley rats.  
Experimental 
Chemicals and solvents 
Compound CDRI-85/92 was synthesised in house (purity >99%) and was used in the 
present study. HPLC grade acetonitrile was purchased from Ranbaxy Laboratories, (SAS 
Nagar, India).  Analytical grade glacial acetic acid was procured from Qualigens Fine 
Chemicals, (Bombay, India). Ammonium acetate was obtained from HIPersolv, (England, 
UK). Triple distilled water from all Quartz glass apparatus was used in the preparation of 
the buffer. Blood was collected from healthy male Sprague Dawley  rats and was 
centrifuged to separate serum so as to generate a drug-free serum pool. 
Preparation of formulations  
Solution formulations (10 and 20 mg/ml) of CDRI-85/92 were prepared by dissolving 200 
and 400 mg in 20 ml of triple distilled water (isotonic solution: compound was completely 
soluble at the given strength) for oral and intravenous dosing. 
Animal study 
Adult healthy male Sprague Dawley  rats weighing 250 ±  25 g were obtained from 
Laboratory Animal Division of the Central Drug Research Institute (Lucknow, India) and   Bioavailability and Excretion Studies of a New PPI  169 
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were maintained under standard in house conditions. They were kept in plastic cages and 
were allowed free access to standard pellet diet (Lipton India Ltd., Bangalore) and tap 
water  ad libitum.  All experiments in rats, euthanasia and disposal of carcasses were 
carried out as per the guidelines laid down by the local ethics committee for animal 
experimentation. Care was taken to minimize the trauma as a result of pain during all the 
surgical procedures and blood sampling by the use of ether anesthesia. The rats were 
maintained on a 12 h light-dark cycle for at least one week before use. 
Instrumentation and chromatographic conditions 
The HPLC system consisted of a solvent delivery system with a controller (Kontron HPLC 
System, Unicam, Cambridge, UK) equipped with a 7125 injector (Rheodyne, Berkely, 
USA) fitted with a fixed 20-µl loop and a Kontron UV spectrophotometer detector (Uvikon 
730S LC set at 250 nm). The samples were injected with a 100 µl syringe. Separation was 
achieved on a C-18 column (5 µm, 220 x 4.6 mm, id), coupled with a guard column packed 
with the same material (5 µm, 30 x 4.6 mm, id), (E-Merck, Darmstadt FR Germany; No. 
619429).  The  chromatograms were integrated using CR1B Chromatopac integrator 
(Shimadzu, Kyoto, Japan). The HPLC system was equilibrated for approximately 30 min at 
a flow rate of 1 ml/min before analysis commenced. A vortex-mixer (Thermolyne, India), 
ultrasonic bath (Bransonic, Shelto, CY), a Model SVC-220H Speed vac concentrator 
(Savant, NY) or Heto/Maxi Dry Plus, Germany) and a Model C-30 centrifuge (Remi, India) 
were used for sample preparations. The mobile phase was prepared by mixing methanol, 
acetonitrile and 10  mM ammonium acetate buffer (pH 4.0) (filtered through 0.22  µm 
Millipore filter) (29:1:70, v/v/v). The mobile phase was degassed for 15 min in the sonicator 
before use and was pumped at a flow rate of 1 ml/min.  The chromatography was 
performed at ambient temperature. 
Pharmacokinetics of CDRI-85/92 
As the first step of experiment, an aqueous solution formulation of the compound was 
administered intravenously to conscious rats via the caudal vein at a dose of 20 mg/kg in a 
volume of approximately 1.0 ml/kg/rat. Before the experiment, the tail was cleaned with 
luke warm water and the caudal vein was dilated using xylene. Blood (approx. 1.2 ml) was 
collected by cardiac puncture under light ether anesthesia at 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 
6, 8, 12, 24 and 48 h post dose. In the second study, conscious rats, fasted overnight, 
were fed orally at a dose of 20 mg/kg in a volume of 2.0 ml/kg/rat. After drug delivery, 
blood was collected at the same time points used in the intravenous study. Three rats 
were utilized for each time point and not more than three or four (later in case of 48 hr) 
blood samples from each rat, two of which were by intracardiac during the absorption-
distribution phase (till 5 hr)  and one from the venecava in the terminal phase  (6 hr 
onwards), was withdrawn. Together in two sets of studies, there were 24 rats. (Pl refer to 
Sampling schedule: Table 1). The total volume of the blood withdrawn within 24 h from 
cardiac puncture was less than 10% of the total blood volume. Blood was allowed to clot in 
sealed glass tubes and centrifuged at 2000 rpm. The serum was separated and stored at 
−60°C until analyses. 
Urinary, fecal and biliary excretion of CDRI-85/92  
Urinary, fecal and biliary excretion of CDRI-85/92 was studied in rats (n=3 per group) after 
a single 20 mg/kg oral and intravenous dose. Following treatment with CDRI-85/92, urine 170  P. Srivastava:   
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and feces samples were collected during 24 h with 12 h intervals. Urine was measured 
and kept in parafilm sealed tubes at −60°C till analyses. Feces samples were dried at 
37°C, weighed, ground to fine powder using mortar-pestle and stored in desiccator until 
analyses. Untreated rats were housed in metabolic cages with food and water ad libitum 
and their feces and urine collected to serve as blank samples for method development and 
validation. 
Tab. 1.   Sampling Schedule during oral and iv treatment 
Animal grouping 
Groups (n=3) 
Time points (hr) 
0.08  0.25  0.5  1  2  3  4  5  6  8  12  24  48 
A                                        
B                                         
C                                         
D                                         
 
For biliary excretion study, bile duct of the rats was surgically cannulated under light ether 
anesthesia [4]. Rats were dosed with the solution formulation of CDRI-85/92 at 20 mg/kg 
orally or intravenously and placed in Bollman cages. Bile samples were collected in glass 
tubes at 0–12 and 12–24 h post dose. The volume of the samples were recorded and 
stored at −60°C until analyses. 
Partition coefficient (log P) 
Determination of log P was carried out according to the method of Said et al. (1996) [5]. 1-
Octanol and 20 mM phosphate buffer (pH, 7.4) were mutually saturated for 6 h on 
magnetic stirrer and separated. A solution of the compound (1 mg/ml) was prepared in 
octanol saturated buffer. Buffer (2 ml) and octanol containing CDRI-85/92 were placed in 
seven glass tubes and screw capped. These tubes were tumble-mixed for 2 h at 25°C at 
about 100 inversions/min.  The organic and aqueous phases were separated by 
centrifugation at 2500 rev/min for 20 min. The concentration of the compound in aqueous 
and organic phase was determined by HPLC after a suitable dilution in mobile phase. The 
log P was calculated from the following equation: 
Log P = log
Coctanol
Cbuffer
 
where Coctanol and Cbuffer are the concentrations of the compound in octanol and buffer, 
respectively.  Further, log P values {Log P= log10 (pKa)} were also calculated after 
conducting potentiometric titration. It was carried out manually using a pH electrode and a 
variable volume pipette. A solution of the compound (1 mg/ml) was prepared in water and 
it was titrated with a 0.1 M NaOH solution, pH was measured simultaneously.  The 
equivalence point (pKa- partition coefficient) was estimated from the inflection point in the 
titration curve from the plot between pH and volume of mL of NaOH solution.  
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Bioanalyses in Serum 
Serum concentrations of the compound were determined by HPLC method as described 
by Srivastava & Gupta (2002) [6] with minor modification. Briefly, to 0.5 ml serum (blank, 
spiked or test) in 10 ml test tube 1.5 ml of acetonitrile was added and vortex-mixed for 15 
sec. The tubes were kept in fridge for 30 min for complete protein precipitation, vortex-
mixed for 1 min and centrifuged at 1000 x g for 10 min at 4°C. Supernatant (1.5 ml) was 
transferred to a 10 ml conical tube without disturbing the lower precipitate pellet and 
evaporated to dryness in Savant speed vac concentrator. The residue was reconstituted in 
0.1 ml of mobile phase, centrifuged at 1000 x g for 10 min and the resulting solution was 
injected onto the HPLC system. 
Bioanalyses in Urine, bile and feces 
The HPLC method described above was validated for estimation of CDRI-85/92 in urine 
and bile by assaying the spiked control samples in these biomatrics at three concentration 
levels (20, 50 and 100 ng/ml of the drug). To have a robust method, inter- and intra-day 
validation was also conducted (Table 2).  
Tab. 2.  Intra- and Inter-day accuracy and precision in urine, feces and bile samples 
Nominal 
Concentrati
on (ng/mL) 
Observed 
Concentration 
(ng/mL) 
Accuracy %  Precision (% RSD) 
  Urine  Feces  Bile  Urine  Feces  Bile  Urine  Feces  Bile 
Intra Day 
20  20.12  19.87  19.74  100.6  99.35  98.7  10.93  11.58  9.84 
50  49.45  48.26  49.67  98.9  96.52  99.34  7.31  8.32  7.54 
100  98.13  97.99  99.77  98.13  97.99  99.77  6.27  15.56  3.11 
Inter Day 
20  20.67  20.03  20.84  103.35  100.15  104.2  11.78  5.45  10.99 
50  51.23  47.29  51.56  102.46  94.58  103.1  8.23  12.35  10.59 
100  102.67  99.78  100.1  102.67  99.78  100.1  5.28  6.75  3.93 
 
For the preparation of the spiked control feces samples, weighed (25 mg) quantities of 
drug-free powdered feces were transferred to different glass tubes, fortified with 
appropriated volume of working dilutions of CDRI-85/92 prepared in methanol, mixed by 
gentle tapping and allowed to stand at room temperature for drying. The blank, spiked or 
test samples were moistened with 0.2 ml of KH2PO4 buffer (20 mM, pH 3.0) followed by 
addition of 1.0 ml of acetonitrile for protein precipitation.  The tubes were sealed with 
parafilm and allowed to stand at room temperature with frequent vortexing. Supernatant 
were processed as described above for serum samples.  For each analytical run, a 
calibration curve was constructed using peak response against the concentration in 
calibration standards prepared in same biomatrix. 
Data analyses 
After oral dose, serum peak concentration (Cmax) and the time to reach peak concentration 
(Tmax) were derived directly from the original data. The serum concentration-time data from 172  P. Srivastava:   
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intravenous and oral dosed rats were fitted to WinNonlin programme (version 1.5) to 
calculate various pharmacokinetic parameters (like AUC, Cl and Vd). The bioavailability for 
oral dose was calculated using the following equation: 
% Bioavailability = 
AUCoral × Doseiv
AUCiv × Doseoral
 × 100 
The amount, cumulative amount and % of the administered dose excreted via urine, bile 
and feces were calculated.  
Results and Discussion 
Proton pump inhibitors (PPIs) are highly effective and well tolerated therapeutic agents, 
making them the drug of choice for the treatment of patients having increased gastric acid 
secretion [7]. Here, we present the result of pharmacokinetics and excretion studies of 
CDRI-85/92, a proton pump inhibitor, developed by our Institute. 
The chromatographic conditions and the extraction procedure gave a clean chromatogram 
for the compound in the biometrics. The procedure of sample preparation was easy and 
required a simple protein precipitation by acetonitrile. Recovery from serum varied from 89 
to 94% with coefficients of variation less than 5.6%. The moderate analysis time (10 min) 
together with rapid sample preparation allowed rapid analyses. The calibration curve was 
linear over the range 1.25–200 ng/ml. Using 0.5 ml serum, the lower limit of quantitation 
was 1.25 ng/ml after a five-fold concentration. The mean observed concentrations of the 
quality control samples deviated less than 10% from nominal values for the compound and 
the highest between and within-assay precision (coefficient of variation) was <15%. The 
HPLC method provided reproducible estimates of the compound in serum with sufficient 
sensitivity to allow pharmacokinetic and bioavailability studies. Here we have presented 
the intra- and inter-day accuracy and precision data for urine, feces and bile (Table 2). 
The log P of the compound CDRI-85/92 was 0.53  ±  0.11 and 0.55 ± 0.18 by octanol 
partition and potentiometric titration, respectively. Being hydrophilic, it should be eliminated 
at a faster rate. Log P in the range of 0-3 [8] also points towards the suitability of the CDRI-
85/92 for oral administration. 
The bioavailability of CDRI-85/92 has not been reported to date.  In this study, the 
pharmacokinetics was estimated in male Sprague Dawley rats after 20 mg/kg oral and 
intravenous dose. Since the compound was freely soluble in water we had preferred 
aqueous solution of CDRI-85/92 in iv and oral treatment. The serum concentration-time 
data for the compound after intravenous and oral administration is shown in Figure 2. After 
intravenous administration, CDRI-85/92 was detected in serum up to 12 h. The serum 
concentration-time data was best fitted to two-compartment open model with elimination 
from a central compartment (using WinNonlin). Table 3 summarizes the pharmacokinetic 
parameters calculated from the serum concentration-time data.  CDRI-85/92 was 
eliminated with an elimination half-life of 2.1 h and may have a longer duration of acid 
inhibition. Large volume of distribution (greater than 0.7 L/kg in case of rats) indicated the 
availability of compound in the tissue to exert its prolonged action. A PPI with a longer half-
life should induce more prolonged blockade of proton pumps and is hence likely to bring 
about greater suppression of gastric acid secretion [9]. Currently available benzimidazole-  Bioavailability and Excretion Studies of a New PPI  173 
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based PPIs have half-lives of 1–2 h in human [10, 11]. The half-life of omeprazole is less 
than 5 min in rats [12], in comparison CDRI-85/92 has a half-life of 2 hr in rats which can 
lead to superior and sustained control of acid secretion at night [10].  
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Fig. 2.  Concentration-time profile of CDRI-85/92 after 20 mg/kg oral and intravenous 
treatments 
Following 20 mg/kg oral administration, the compound showed peak concentration (Cmax) 
of 469.2 ± 45.5 ng/ml after 1 h of dose (absorption phase). The compound appeared in the 
blood as early as 5 min post oral treatment with Cmax occurring at 1 h post dose (Table 3). 
The AUC (882 ng.h/ml) was about half as compared to that  after intravenous 
administration (1251 ng.h/ml). The systemic bioavailability (F) of the compound was 70.5% 
after oral administration. As a result of prolonged absorption, as indicated by an MAT of 
2.8 h, the MRT (3.9 h) after oral administration was considerably longer than that observed 
after an intravenous administration (1.1 h). The pharmacokinetic data corroborates with 
the protein binding (32%) and pH independent absorption profiles of CDRI-85/92 [13]. 
Some of the oral pharmacokinetics studies of CDRI-85/92 and its ester prodrug have also 
been reported previously [14, 15]. However, they reflect only the comparison of the oral 
pharmacokinetics of CDRI-85/92 and its ester derivative in different formulation (not 
aqueous) since ester prodrug was not fairly water soluble. This might be the reason that 
an increased Cmax and T1/2 was noticed based on the well known formulation enhancement 
effects.  
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Tab. 3.   Pharmacokinetic parameters of CDRI-85/92 after 20 mg/kg in rats 
Parameters  IV Treatment  Oral Treatment 
Cmax (ng/ml)  4907.2  469.2 
Tmax (h)  –  1.00 
Elimination t1/2 (h)  2.1   
AUC0-∞ (ng.h/ml)  1251  882 
Cl (L/h)  1.1   
Vd (L/kg)  3.7   
MRT (h)  1.1  3.9 
Bioavailability (%)  –  70.5 
MAT (h)  –  2.8 
Cmax, peak concentration; Tmax, time to Cmax; elimination t1/2, 
elimination half-life; AUC0-∞, area under the concentration-time 
curve from zero to infinity; Cl, Clearance; Vd, volume of 
distribution; MRT, mean residence time; MAT (mean absorption 
time) = MRToral−MRTIV. 
 
Excretion of CDRI-85/92 was studied in rats at 20 mg/kg oral and intravenous dosage 
regimen. Urinary excretion of CDRI-85/92 was 4.2 ± 1.1 and 15.7 ± 3.3% of the oral and 
intravenously administered CDRI-85/92 dose, respectively (Table 4).  Further, in bile-
cannulated rats it was found to be 1.7 ± 0.8 and 16.8 ± 2.7%, respectively. In all the cases, 
the amount of the drug excreted was much more in the time range of 0-12 h as compared 
to 12-24 h.  No difference was observed in the urinary excretion of CDRI-85/92 when 
comparison was made between cannulated and non-cannulated rats after intravenous 
treatment. However, bile duct cannulated rats showed difference in urinary excretion after 
oral dose. Fecal excretion of CDRI-85/92 up to 24 h amounted to 1.2 ± 0.6% and 0.08 ± 
0.08% of the oral and intravenously administered CDRI-85/92 dose, respectively (Table 4). 
Biliary excretion of CDRI-85/92 (up to 24 h) after oral administration was found to be 0.37 
± 0.12% of the administrated dose whereas in case of intravenous treatment, the fecal and 
biliary levels of CDRI-85/92 were below the quantitation limits.  Further, the excretion 
parameters (Table 5) ie. fe: fraction of drug excreted, Kel: elimination rate contant, Ke: 
excretion rate constant were calculated based on the semi log plot between ΔU/Δt versus 
Timemidpoint (Fig. 3). However, a disadvantage of this plot is that the error present in "real" 
data can obscure the straight line and lead to results which lack precision. Also, it was 
difficult to collect frequent, accurately timed urine samples. This is especially true when the 
elimination half-life is small, as is the case with our compound. The results thus negate the 
enterohepatic recycling of the drug, which corroborates with the single AUC and Tmax 
values we obtained in the concentration-time profile. The excretion data clearly state that 
renal clearance is one of the major means for the excretion of CDRI-85/92 in urine. 
Further, a trans-isomer of CDRI-85/92 was detected in the urine samples after oral 
treatment of CDRI-85/92. The data obtained in the pharmacokinetics and excretion studies 
corroborates with the metabolism studies of the compound in which very slow metabolism 
was noticed by glutathione-S-transferases with the formation of trans-isoform [16]. This is 
also evident by low clearance of CDRI-85/92. This clearly points towards the hydrophilic 
nature of the compound and correlates with the log P values obtained.    Bioavailability and Excretion Studies of a New PPI  175 
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Tab. 4.  Excretion Profile of CDRI-85/92 dose in rat urine, feces and bile after 20 mg/kg 
oral and intravenous (iv) treatment 
Treatment 
% of dose recovered 
Urine  Feces  Bile 
0–12 h  12–24 h  Total  0–12 h  12–24 h  Total  0–12 h  12–24 h  Total 
Oral (NC)  3.7  0.5  4.2  1.0  0.2  1.2  –  –  – 
IV (NC)  15.7  ND  15.7  0.05  0.02  0.08  –  –  – 
Oral (BC)  1.5  0.2  1.7  –  –  –  0.3  0.08  0.37 
IV (BC)  16.8  ND  16.8  –  –  –  ND  ND  – 
NC, non-cannulated; BC, bile duct cannulated; ND, not detected. 
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Fig. 3.   Representative (urine oral noncannulated) Semi-log Plot of ΔU/Δt versus Time 
midpoint, where Kel is elimination rate contant, Ke is excretion rate constant  
Tab. 5.  Excretion Parameters of CDRI-85/92 after 20 mg/kg dose in rat urine, feces and 
bile after oral and intravenous (iv) treatment 
Treatment 
Excretion Parameters 
Urine  Feces  Bile 
fe  Ke 
(hr
−1) 
Kel 
(hr
−1)  fe  Ke 
(hr
−1) 
Kel 
(hr
−1)  fe  Ke 
(hr
−1) 
Kel 
(hr
−1) 
Oral (NC)  0.56  0.04  0.07  0.012  0.07  0.06  –  –  – 
IV (NC)  0.9  0.09  0.1  0.0008  0.15  0.03  –  –  – 
Oral (BC)  0.83  0.06  0.07  –  –  –  0.0037  0.1  0.048 
IV (BC)  0.90  0.04  0.05  –  –  –  –  –  – 
where fe is fraction excreted, Kel is elimination rate contant, Ke is excretion rate constant. 
 
In conclusion, the results of this study provide the complete analyses of pharmacokinetics 
and excretion of CDRI-85/92 in Sprague Dawley rats, one of the preclinical species used 
in toxicological studies.  Pharmacokinetic parameters of CDRI-85/92, after oral and 
intravenous treatment, depict that the compound has an adequate bioavailability. Excretion 
studies reveal the involvement of renal  clearance of the compound (15% of the 
administered dose) via urine. 176  P. Srivastava:   
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